Back to Search
Start Over
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
- Source :
-
Theranostics [Theranostics] 2020 Feb 03; Vol. 10 (6), pp. 2645-2658. Date of Electronic Publication: 2020 Feb 03 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Rationale : CD38 is a target for the therapy of multiple myeloma (MM) with monoclonal antibodies such as daratumumab and isatuximab. Since MM patients exhibit a high rate of relapse, the development of new biologics targeting alternative CD38 epitopes is desirable. The discovery of single-domain antibodies (nanobodies) has opened the way for a new generation of antitumor therapeutics. We report the generation of nanobody-based humanized IgG1 heavy chain antibodies (hcAbs) with a high specificity and affinity that recognize three different and non-overlapping epitopes of CD38 and compare their cytotoxicity against CD38-expressing hematological cancer cells in vitro , ex vivo and in vivo . Methods : We generated three humanized hcAbs (WF211-hcAb, MU1067-hcAb, JK36-hcAb) that recognize three different non-overlapping epitopes (E1, E2, E3) of CD38 by fusion of llama-derived nanobodies to the hinge- and Fc-domains of human IgG1. WF211-hcAb shares the binding epitope E1 with daratumumab. We compared the capacity of these CD38-specific hcAbs and daratumumab to induce CDC and ADCC in CD38-expressing tumor cell lines in vitro and in patient MM cells ex vivo as well as effects on xenograft tumor growth and survival in vivo . Results : CD38-specific heavy chain antibodies (WF211-hcAb, MU1067-hcAb, JK36-hcAb) potently induced antibody-dependent cellular cytotoxicity (ADCC) in CD38-expressing tumor cell lines and in primary patient MM cells, but only little if any complement-dependent cytotoxicity (CDC). In vivo, CD38-specific heavy chain antibodies significantly reduced the growth of systemic lymphomas and prolonged survival of tumor bearing SCID mice. Conclusions : CD38-specific nanobody-based humanized IgG1 heavy chain antibodies mediate cytotoxicity against CD38-expressing hematological cancer cells in vitro , ex vivo and in vivo . These promising results of our study indicate that CD38-specific hcAbs warrant further clinical development as therapeutics for multiple myeloma and other hematological malignancies.<br />Competing Interests: Competing Interests: K.S., W.F., L.S., S.M., P.B., and F.K.-N. are co-inventors on a patent application on CD38-specific nanobodies. F.H. and F.K.-N. receive a share of antibody and protein sales via MediGate GmbH, a wholly owned subsidiary of the University Medical Center Hamburg-Eppendorf.<br /> (© The author(s).)
- Subjects :
- Aged
Animals
Cell Line, Tumor
Epitopes immunology
Female
Humans
Male
Mice
Mice, SCID
Middle Aged
ADP-ribosyl Cyclase 1 immunology
Antibodies, Monoclonal, Humanized therapeutic use
Hematologic Neoplasms drug therapy
Immunoglobulin G therapeutic use
Immunoglobulin Heavy Chains therapeutic use
Membrane Glycoproteins immunology
Multiple Myeloma drug therapy
Single-Domain Antibodies therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1838-7640
- Volume :
- 10
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Theranostics
- Publication Type :
- Academic Journal
- Accession number :
- 32194826
- Full Text :
- https://doi.org/10.7150/thno.38533